Treatment Patterns and Clinical Outcomes of Chronic Urticaria: Two-year Follow-up Results from the Scandinavian AWARE Study


  • Simon F. Thomsen
  • Ellen C. Pritzier
  • Chris D. Anderson
  • Siri Juvik
  • Nicolas V. Baust
  • Rikke Dodge
  • Anna-Karin Dahlborn
  • Christian Vestergaard Department of Dermatology, Aarhus University Hospital, Palle Juul-Jensens Blvd. 161, DK-8200 Aarhus, Denmark



chronic urticaria, quality of life, patient reported outcomes, omalizumab, AWARE


The AWARE (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) study investigated outcomes in patients with chronic urticaria refractory to H1-antihistamine. The objective of the current study was to analyse the effects of treatment on patients’ symptoms and quality of life for a period of up to 2 years. Over the 2 years, there was clear improvement in the high rates of disease burden from baseline, as evidenced by lower scores for disease severity scales, better quality of life, and a decreasing rate of medical resource utilization. However, this is the result of treatment adherence to the guidelines in highly specialized Scandinavian urticaria centres, and has its basis in the relatively low treatment intensity and control at enrolment. There is a need for greater adherence to the treatment guidelines and better management of antihistamine-refractory chronic urticaria.


Download data is not yet available.


Schaefer P. Acute and chronic urticaria: evaluation and treatment. Am Fam Physician 2017; 95: 717-724.

Sanchez-Borges M, Asero R, Ansotegui IJ, Baiardini I, Bernstein JA, Canonica GW, et al. Diagnosis and treatment of urticaria and angioedema: a worldwide perspective. World Allergy Organ J 2012; 5: 125-147. DOI:

Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014; 69: 868-887. DOI:

Kolkhir P, Church MK, Weller K, Metz M, Schmetzer O, Maurer M. Autoimmune chronic spontaneous urticaria: what we know and what we do not know. J Allergy Clin Immunol 2017; 139: 1772-1781. DOI:

Radonjic-Hoesli S, Hofmeier KS, Micaletto S, Schmid-Grendelmeier P, Bircher A, Simon D. Urticaria and angioedema: an update on classification and pathogenesis. Clin Rev Allergy Immunol 2018; 54: 88-101. DOI:

Maurer M, Schütz A, Weller K, Schoepke N, Peveling-Oberhag A, Staubach P, et al. Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial. J Allergy Clin Immunol 2017; 140: 870-873. DOI:

Metz M, Schutz A, Weller K, Gorczyza M, Zimmer S, Staubach P, et al. Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial. J Allergy Clin Immunol 2017; 140: 864-867. DOI:

Dressler C, Werner RN, Eisert L, Zuberbier T, Nast A, Maurer M. Chronic inducible urticaria: a systematic review of treatment options. J Allergy Clin Immunol 2018; 141: 1726-1734. DOI:

Sanchez Jorge J, Sanchez A, Cardona R. Prevalence of drugs as triggers of exacerbations in chronic urticaria. J Investig Allergol Clin Immunol 2019; 29: 112-117. DOI:

Maurer M, Abuzakouk M, Berard F, Canonica W, Oude Elberink H, Giménez-Arnau A, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy 2017; 72: 2005-2016. DOI:

Balp MM, Khalil S, Tian H, Gabriel S, Vietri J, Zuberbier T. Burden of chronic urticaria relative to psoriasis in five European countries. J Eur Acad Dermatol Venereol 2018; 32: 282-290. DOI:

Moestrup K, Ghazanfar MN, Thomsen SF. Patient-reported outcomes (PROs) in chronic urticaria. Int J Dermatol 2017; 56: 1342-1348. DOI:

Dias GA, Pires GV, Valle SO, Dortas SD Júnior, Levy S, França AT, et al. Impact of chronic urticaria on the quality of life of patients followed up at a university hospital. An Bras Dermatol 2016; 91: 754-759. DOI:

Larrea-Baca I, Gurpegui-Resano M. Improvement in the quality of life of patients with chronic spontaneous urticaria treated with omalizumab in real life. Enferm Clin 2017; 27: 361-368. DOI: DOI:

Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy 2011; 66: 317-330. DOI:

Antia C, Baquerizo K, Korman A, Alikhan A, Bernstein JA. Urticaria: a comprehensive review: treatment of chronic urticaria, special populations, and disease outcomes. J Am Acad Dermatol 2018; 79: 617-633. DOI:

Thomsen SF, Pritzier EC, Anderson CD, Vaugelade-Baust N, Dodge R, Dahlborn AK, et al. Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark: baseline results from the non-interventional multicentre AWARE study. J Eur Acad Dermatol Venereol 2017; 31: 1048-1055. DOI:

Houghton K, Costa C, Dabove F, Ensina LF, Giménez-Arnau A, et al. Differences in chronic spontaneous urticaria between Europe and Central/South America: results of the multi-center real world AWARE study. World Allergy Organ J 2018; 11: 32. DOI:



How to Cite

Thomsen, S. F., Pritzier, E. C., Anderson, C. D., Juvik, S., Baust, N. V., Dodge, R., Dahlborn, A.-K., & Vestergaard, C. (2022). Treatment Patterns and Clinical Outcomes of Chronic Urticaria: Two-year Follow-up Results from the Scandinavian AWARE Study. Acta Dermato-Venereologica, 102, adv00689.